WO2012050393A3 - 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 - Google Patents

리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 Download PDF

Info

Publication number
WO2012050393A3
WO2012050393A3 PCT/KR2011/007667 KR2011007667W WO2012050393A3 WO 2012050393 A3 WO2012050393 A3 WO 2012050393A3 KR 2011007667 W KR2011007667 W KR 2011007667W WO 2012050393 A3 WO2012050393 A3 WO 2012050393A3
Authority
WO
WIPO (PCT)
Prior art keywords
reverse
production method
novel compound
turn mimetic
use therefor
Prior art date
Application number
PCT/KR2011/007667
Other languages
English (en)
French (fr)
Other versions
WO2012050393A2 (ko
Inventor
정재욱
김미정
이용실
마상호
조영석
이상학
나영준
강명주
박월성
Original Assignee
제이더블유중외제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이더블유중외제약 주식회사 filed Critical 제이더블유중외제약 주식회사
Priority to US13/878,990 priority Critical patent/US8940739B2/en
Priority to EP11832780.8A priority patent/EP2628741B1/en
Priority to JP2013533778A priority patent/JP5809279B2/ja
Priority to CN201180049821.9A priority patent/CN103209982B/zh
Priority to KR1020137006430A priority patent/KR101892575B1/ko
Priority to ES11832780.8T priority patent/ES2552462T3/es
Publication of WO2012050393A2 publication Critical patent/WO2012050393A2/ko
Publication of WO2012050393A3 publication Critical patent/WO2012050393A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

본 발명은 피라지노트리아지논 (Pyrazino-triazinone)을 기본 구조로 갖는，리버스-턴 유사체의 신규한 화합물 및 이의 제조방법에 관한 것이고， 또한 상기 화합물의 항암효과 등의 질병치료제， 특히 급성 골수성 백혈병의 치료제로서의 용도에 관한 것이다.
PCT/KR2011/007667 2010-10-14 2011-10-14 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 WO2012050393A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US13/878,990 US8940739B2 (en) 2010-10-14 2011-10-14 Compound of a reverse-turn mimetic and a production method and use therefor
EP11832780.8A EP2628741B1 (en) 2010-10-14 2011-10-14 Novel compound of a reverse-turn mimetic and a production method and use therefor
JP2013533778A JP5809279B2 (ja) 2010-10-14 2011-10-14 リバースターン類似体の新規な化合物およびその製造方法と用途
CN201180049821.9A CN103209982B (zh) 2010-10-14 2011-10-14 反转模拟物的化合物、其制造方法及其用途
KR1020137006430A KR101892575B1 (ko) 2010-10-14 2011-10-14 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
ES11832780.8T ES2552462T3 (es) 2010-10-14 2011-10-14 Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0100490 2010-10-14
KR20100100490 2010-10-14

Publications (2)

Publication Number Publication Date
WO2012050393A2 WO2012050393A2 (ko) 2012-04-19
WO2012050393A3 true WO2012050393A3 (ko) 2012-07-26

Family

ID=45938820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007667 WO2012050393A2 (ko) 2010-10-14 2011-10-14 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도

Country Status (8)

Country Link
US (1) US8940739B2 (ko)
EP (1) EP2628741B1 (ko)
JP (1) JP5809279B2 (ko)
KR (1) KR101892575B1 (ko)
CN (1) CN103209982B (ko)
ES (1) ES2552462T3 (ko)
TW (1) TWI531573B (ko)
WO (1) WO2012050393A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353119B2 (en) 2011-08-09 2016-05-31 Jw Pharmaceutical Corporation Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
ES2577863T3 (es) 2011-08-09 2016-07-19 Jw Pharmaceutical Corporation Composición para la prevención y el tratamiento del cáncer de pulmón de células no pequeñas, que contiene derivados de pirazino-triazina
US9174998B2 (en) * 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
EP3193600A4 (en) * 2014-09-10 2018-05-23 Epizyme, Inc. Smyd inhibitors
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
CA2986999C (en) 2015-06-23 2023-08-08 Eisai R&D Management Co., Ltd. Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide
KR102444835B1 (ko) 2016-05-26 2022-09-19 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
KR20220000460A (ko) * 2020-06-26 2022-01-04 제이더블유중외제약 주식회사 폐섬유화증 치료용 조성물
WO2022231377A1 (ko) * 2021-04-29 2022-11-03 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 및 그의 용도
WO2023178094A2 (en) * 2022-03-14 2023-09-21 Purdue Research Foundation Spleen tyrosine kinase inhibitor, composition, and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008941B2 (en) * 2001-05-16 2006-03-07 Myriad Genetics, Inc. Reverse-turn mimetics and methods relating thereto
KR20100085107A (ko) * 2007-10-15 2010-07-28 주식회사 중외제약 리버스턴 유사체의 신규 화합물 및 그의 용도(3)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
EP0656907A1 (en) 1992-08-06 1995-06-14 Molecumetics, Ltd. Conformationally restricted mimetics of reverse turns and peptides containing the same
US6013458A (en) 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US7662960B2 (en) 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
ATE398129T1 (de) * 2001-10-12 2008-07-15 Choongwae Pharma Corp Reverse-turn-mimetika und diese betreffendes verfahren
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
CA2537099A1 (en) 2003-08-28 2005-03-10 Choongwae Pharma Corporation Modulation of .beta.-catenin/tcf activated transcription
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
ES2570994T3 (es) 2005-11-08 2016-05-23 Choongwae Pharma Corp Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer
ATE446509T1 (de) 2005-11-28 2009-11-15 Choongwae Pharma Corp Serumfreie expansion von zellen in kultur
KR20090026302A (ko) 2006-05-30 2009-03-12 주식회사 중외제약 줄기세포 분화의 유도 또는 억제를 위한 조성물
SG175045A1 (en) * 2009-04-15 2011-11-28 Jw Pharmaceutical Corp Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008941B2 (en) * 2001-05-16 2006-03-07 Myriad Genetics, Inc. Reverse-turn mimetics and methods relating thereto
KR20100085107A (ko) * 2007-10-15 2010-07-28 주식회사 중외제약 리버스턴 유사체의 신규 화합물 및 그의 용도(3)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2628741A4 *

Also Published As

Publication number Publication date
KR20140020224A (ko) 2014-02-18
TW201219395A (en) 2012-05-16
US20130196972A1 (en) 2013-08-01
EP2628741A4 (en) 2013-08-21
US8940739B2 (en) 2015-01-27
JP5809279B2 (ja) 2015-11-10
KR101892575B1 (ko) 2018-08-31
CN103209982B (zh) 2016-03-16
EP2628741A2 (en) 2013-08-21
JP2013540774A (ja) 2013-11-07
EP2628741B1 (en) 2015-10-07
TWI531573B (zh) 2016-05-01
ES2552462T3 (es) 2015-11-30
WO2012050393A2 (ko) 2012-04-19
CN103209982A (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
WO2012050393A3 (ko) 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
IL291613A (en) Anticoagulant monoclonal antibodies (anti–factor xii/fxiia), method for their preparation, pharmaceutical compound containing them and medical uses
WO2012138981A3 (en) New intermediates and processes for preparing ticagrelor
WO2013021279A3 (en) Highly galactosylated antibodies
WO2010115552A8 (en) Bispecific anti-erbb-3/anti-c-met antibodies
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
WO2011093825A3 (en) Effervescent dosage forms comprising cephalosporin antibiotic
WO2012038504A3 (en) Breast cancer therapeutics
WO2013165921A3 (en) Therapeutic use of chardonnay seed products
WO2013188417A3 (en) Treatment and prevention of cardiovascular disease and thrombosis
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2014089177A3 (en) Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
WO2010136104A3 (en) Anti-dandruff agents
WO2012064743A3 (en) Methods for improving heart function
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
WO2012154879A3 (en) Autophagy inhibitors
WO2011088020A9 (en) Modified saponins for the treatment of fungal infections
MX339772B (es) Metodo y composicion para producir azucar clarificada.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180049821.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11832780

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20137006430

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13878990

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011832780

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013533778

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE